Current research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing encouraging outcomes in addressing excess mass and type 2 disease. Preclinical evidence suggest a distinct mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/